Profit is at the heart of every IPR, says Kyle Bass

Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review (IPR) filing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

From the courtroom: Hikma v Amarin SCOTUS oral arguments

30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.

Americas

Blow for Masimo’s fight with Apple as case against US Customs dismissed

29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

More features

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Report: 85% of in-house counsel want IP service providers to embrace AI

Moderna loses key mRNA patent in European vaccine fight

Boston-based patent expert departs Mintz for major West Coast firm

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Ligand buys biotech in $739m cash deal with litigation sweetener

CureVac targets Moderna with 10-patent suit over Spikevax

Profit is at the heart of every IPR, says Kyle Bass

More on this story

Editor's picks

Editor's picks

More features